Healthcare / BiotechnologyNasdaqCM
$18.59
-2.45 (-11.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-75.9M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$918M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-38.3%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-127.4M · FCF $-94.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-127.4M | $-127.4M | — | $-75.5M | $-51.5M | $-23.0M | $-9.6M |
| EBITDA | $-113.5M | $-113.5M | — | — | — | — | — |
| EPS | -3.19 | -3.19 | — | -100.45 | -73.50 | -65.45 | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.00 | 0.00 | -2.30 | — | — | — | — |
| Current Ratio | 14.29 | 14.29 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-94.9M | $-94.9M | — | $-56.9M | $-39.3M | $-27.6M | — |
| Returns | |||||||
| ROE | -38.3% | -38.3% | — | -69.0% | -40.6% | -13.3% | 72.0% |
| Valuation | |||||||
| P/B | 1.75 | 1.75 | — | — | — | — | — |
| Growth & Yield | |||||||
| EPS Growth | — | — | — | -36.7% | -12.3% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+156.4%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -3.19
Residual
+156.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.